Description

The (S)- enantiomer of ADB-FUBINACA is explained in a 2009 Pfizer patent [3] and has been reported to be a potent agonist of the CB1 receptor and also the CB2 receptor with EC50 values of 1.2 nM as well as 3.5 nM, specifically. ADB-FUBINACA includes a carboxamide team at the 3-indazole setting, like SDB-001 and STS-135. ADB-FUBINACA seems the product of rational medication design, because it differs from AB-FUBINACA only by the replacement of the isopropyl team with a tert-butyl team.

An analogue of ADB-FUBINACA, ADSB-FUB-187, consisting of an extra functionalized carboxamide substituent was lately reported.
Side effects.

One death through coronary arterial thrombosis has actually been linked to ADB-FUBINACA intoxication.
At least an additional 8 deaths in Hungary in 2015 are connected to the use of this product, all fatalities were children listed below 21.
Metabolic rate
Twenty-three ADB-FUBINACA major metabolites were recognized in a number of incubations with cryopreserved human hepatocytes. Significant metabolic paths were alkyl as well as indazole hydroxylation, incurable amide hydrolysis, subsequent glucuronide conjugations, and dehydrogenation.